- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03680352
Pharmacokinetics of Cefepime and AAI101 in Subjects With Renal Insufficiency and Healthy Subjects
Phase 1, Open-label, Parallel Group, Single-dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of AAI101 With Cefepime in Subjects With Varying Degrees of Renal Function
This is a Phase 1, multi-center, open-label, PK and safety study of a single dose of AAI101 in combination with cefepime in male and female subjects with mild renal impairment (Group 1, n = 6), moderate renal impairment (Group 2, n = 6), severe renal impairment (Group 3, n = 6), ESRD requiring dialysis (Group 4, n = 6), and normal renal function (Group 5, n = 6) as defined using the estimated value for creatinine clearance (CLcr) at Screening.
The study consists of a 28-day screening period, followed by a single dose administration of AAI101 in combination with cefepime antibiotic on Day 1, an in house period (assessment period) and follow-up visit. All subjects will be confined to the study site from Day -1 (the day before dosing) until the morning of Day 3. The follow-up visits will occur on Day 7 (±2 days), on Day 14 (±2 days), and on Day 30 (±2 days), if the results of the safety hepatic assessments are abnormal on Day 14 (±2 days).
Group 4 (ESRD requiring dialysis) will have 2 in-house periods (separated by at least 7 days), and will receive the single doses of AAI101 in combination with cefepime antibiotic once after dialysis and once before dialysis. The follow-up visit for Group 4 will occur on Day 7 (±2 days), on Day 14 (±2 days), and on Day 30 (±2 days), if the results of the safety hepatic assessments are abnormal on Day 14 (±2 days), counting from Day 1 of the second period.
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Main Inclusion Criteria
- Adult male or female subjects age 18 to 70 years, inclusive
- BMI 18.0 35.0 kg/m2, inclusive, where BMI (kg/m2) = body weight (kg) / height2 (m2) Subjects with Renal Impairment (in addition)
- Stable renal impairment, defined as no clinically significant change in disease status, as judged by the Investigator Healthy Subjects (in addition)
- Subjects with normal renal function as evidenced by CLcr
- Judged to be in good health in the opinion of the Investigator on the basis of a medical evaluation that reveals the absence of any clinically relevant abnormality OR Subject has a stable disease (e.g., hypertension, hyperlipidemia, diabetes mellitus, hyperthyreosis) under medical control.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: cefepime/AAI101 combination
Investigational drug
|
Fixed dose combination of cefepime and AAI101
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The maximum plasma concentration (Cmax) of cefepime and AAI101
Time Frame: Up to 48 hours post-dose
|
Cmax will be compared before and after administration of a single dose of cefepime/AAI101
|
Up to 48 hours post-dose
|
AUC0-inf: area under the concentration-time curve (AUC) from time 0 extrapolated to infinity of cefepime and AAI101
Time Frame: Up to 48 hours post-dose
|
AUC0-inf will be compared before and after administration of a single dose of cefepime/AAI101
|
Up to 48 hours post-dose
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The number of volunteers with adverse events as a measure of safety and tolerability
Time Frame: Up to 96 hours post-dose
|
Assessments will be made via recording of AEs.
|
Up to 96 hours post-dose
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- AT-102
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on PK in Patients With Various Degrees of Renal Impairment
-
Pfizer's Upjohn has merged with Mylan to form Viatris...TerminatedPK Properties Of Gabapentin In Subjects With Impaired Renal FunctionJapan
-
Rempex Pharmaceuticals (a wholly owned subsidiary...CompletedSubjects With Varying Degrees of Renal Insufficiency and | Subjects With Normal Renal FunctionUnited States
-
Centre hospitalier de Ville-Evrard, FranceUnknownTaking Charge of Cognitive Impairment in Patients With Mood DisordersFrance
-
Stanford UniversityUniversity of Colorado, DenverCompletedThe Pk of IV Ketamine in Children With Heart DiseaseUnited States
-
Nektar TherapeuticsCompletedAdvanced or Metastatic Solid Tumors in Patients With Hepatic ImpairmentUnited States
-
Atlantic Health SystemNot yet recruitingPrevalence of OSA in Patients Hospitalized With COPD Exacerbation
-
State University of New York - Downstate Medical...UnknownPercentage of Change in ONSD During Anesthesia With Sevoflurane Versus Propofol in Two Groups of PatientsUnited States
-
University Medical Center GroningenCompleted
-
Yonsei UniversityWithdrawnPatients in the Treatment of Subjects With All-comer Who Are to Undergo PCI
-
Novartis PharmaceuticalsCompletedProphilaxis of Acute Rejection in Patients Receiving a Renal AllograftSpain
Clinical Trials on cefepime/AAI101
-
AllecraCompleted
-
AllecraMedpace, Inc.CompletedUrinary Tract InfectionsHungary, Czechia, Poland, Slovakia, Ukraine
-
AllecraMedpace, Inc.CompletedUrinary Tract InfectionsUnited States, Serbia, Hungary, Estonia, South Africa, Belarus, Poland, Ukraine, Argentina, Bulgaria, Croatia, Georgia, Latvia, Lithuania, Mexico, Peru, Russian Federation, Slovakia, Spain
-
AllecraCompletedHealthyUnited States
-
Hospital de Clinicas de Porto AlegreUnknownUrinary Tract Infection | Respiratory Tract InfectionBrazil
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedMyelodysplastic Syndromes | Breast Cancer | Primary Myelofibrosis | Multiple Myeloma | Ovarian Epithelial Cancer | Chronic Myelomonocytic Leukemia | Neutropenia | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Splenic Marginal Zone... and other conditionsUnited States
-
WockhardtMedpace, Inc.RecruitingAcute Pyelonephritis | Complicated Urinary Tract InfectionUnited States, China, India, Lithuania, Mexico, Peru, Poland, Bulgaria, Estonia
-
Venatorx Pharmaceuticals, Inc.Department of Health and Human ServicesNot yet recruitingHospital-acquired Pneumonia | Ventilator-associated Pneumonia
-
Venatorx Pharmaceuticals, Inc.CompletedHealthy SubjectsUnited States